116355-19-2 Usage
Description
Imidazo[1,2-a]pyridine, 6-bromo-5-methylis a chemical compound belonging to the imidazopyridine class, characterized by a molecular formula of C8H7BrN2 and a molecular weight of 212.06 g/mol. It is a significant building block in the pharmaceutical industry, utilized for the synthesis of biologically active compounds and serving as an intermediate in the development of pharmaceutical drugs targeting a range of diseases. Its importance extends to medicinal chemistry research and drug discovery.
Uses
Used in Pharmaceutical Industry:
Imidazo[1,2-a]pyridine, 6-bromo-5-methylis used as a building block for the synthesis of various biologically active compounds, contributing to the development of new pharmaceutical drugs. Its role in drug synthesis is crucial for creating molecules with potential therapeutic applications.
Used in Medicinal Chemistry Research:
Imidazo[1,2-a]pyridine, 6-bromo-5-methylis utilized as a starting material in medicinal chemistry research, aiding in the exploration and understanding of new drug candidates and their mechanisms of action.
Used in Drug Discovery:
Imidazo[1,2-a]pyridine, 6-bromo-5-methylplays a vital role in drug discovery efforts, serving as a precursor in the creation of novel therapeutic agents that could address unmet medical needs and improve patient outcomes.
Check Digit Verification of cas no
The CAS Registry Mumber 116355-19-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,6,3,5 and 5 respectively; the second part has 2 digits, 1 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 116355-19:
(8*1)+(7*1)+(6*6)+(5*3)+(4*5)+(3*5)+(2*1)+(1*9)=112
112 % 10 = 2
So 116355-19-2 is a valid CAS Registry Number.
116355-19-2Relevant articles and documents
Imidazo[1,2-a]pyridines. Synthesis and inotropic activity of new 5-imidazo[1,2-a]pyridinyl-2(1H)-pyridinone derivatives
Yamanaka,Miyake,Suda,Ohhara,Ogawa
, p. 1556 - 1567 (2007/10/02)
A series of 1,2-dihydro-5-imidazo[1,2-a]pyridinyl-2(1H)-pyridinones was synthesized and evaluated for positive inotropic activity. 1,2-Dihydro-5-imidazo[1,2-a]pyridin-6-yl-6-methyl-2-oxo-3- pyridinecarbonitrile (11a) hydrochloride monohydrate (E-1020) was found to be a potent and selective inhibitor of phosphodiesterase III and a long-acting, potent, orally active positive inotropic agent. Additional imidazo[1,2-a]pyridin-2-yl (3a), -3-yl (16), -7-yl (20) and -8-yl (24a) compounds were also prepared. Altering the pyridine substitution from the 2-position to the 6-position produced a 2-fold increase in the i.v. cardiotonic potency (ED50) from 52 to 23 μg/kg, while substitution at the 3-, 7- or 8-position reduced potency. In the 2-positional isomers, introduction of halogen groups enhanced the activity and 3-chloro-1,2-dihydro-5-(6-fluoroimidazo[1,2-a]pyridin-2-yl)-6-methyl-2(1H)- pyridinone (3a) was the most potent (i.v. ED50 11 μg/kg) in this seris. E-1020 is presently under development for the treatment of congestive heart failure.
